Publication | Closed Access

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Breast OncologyOncologyMedicinePathologyCdk4/6 InhibitorBreast CancerAnti-cancer AgentCancer TreatmentPhase 2Non-comparative StudyPharmacologyEndocrine-related Cancer